SHENZHEN Hemogen Therapeutic Co., Ltd.

Hemogen, a subsidiary company of BGI Group, adheres to the BGI vision - "Omics for All". Supported by the strong scientific research capabilities of BGI-Research and the strong influence of BGI Group in the medical and health science field, Hemogen is committed to the treatment of hemoglobin diseases and to the goal of "Create a Thalassemia Free World".

Hemogen has two gene editing platforms, lentivirus and CRISPR/Cas, and continues to focus on the research, development, and application of gene therapy vectors and genetic engineering technologies. Hemogen has independent research and development capabilities and a well-established quality management system. At present, Hemogen focuses on the development of "HGI-001 Injection", which was successfully tested by investigator-initiated trials (IITs) and helped five transfusion-dependent β-thalassemia (TDT) patients to achieve transfusion independence (TI) for the long run. The first IIT patient already achieves TI for over 27 months. Hemogen is making every effort to promote investigational new drug application (IND) of HGI-001 Injection. At the same time, the company is developing other product pipelines related to gene therapy and is actively carrying out international registration and international clinical trials.